Wide Ranks

APTO

Aptose Biosciences, Inc.

0.1790

Top Statistics
Market Cap 10 M Forward PE -0.0817 Revenue Growth 0.00 %
Current Ratio 0.00 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash Total Cash Per Share Total Debt
Total Debt To Equity Current Ratio 0.00 Book Value Per Share -0.3650
All Measures
Short Ratio 161.00 % Message Board Id finmb_121269 Shares Short Prior Month 192682
City Toronto Uuid abb612cb-7f65-3d78-b951-26e228236bcd Previous Close 0.1780
First Trade Date Epoch Utc 700 M Book Value -0.3650 Volume 1 M
Last Split Date 1 B Fifty Two Week Low 0.1300 Shares Short Previous Month Date 1 B
Target Median Price 2.00 Audit Risk 9 Max Age 86400
Recommendation Mean 2.00 Sand P52 Week Change 0.3133 Target Mean Price 2.00
Net Income To Common -35800000 Short Percent Of Float 0.0073 Implied Shares Outstanding 59 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Next Fiscal Year End 1 B Held Percent Insiders 0.1639
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 9 Regular Market Previous Close 0.1780 Target Low Price 2.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 0.3628 Open 0.1893
Dividend Yield 0.00 % State ON Time Zone Short Name EST
Board Risk 6 Trailing Eps -2.92 Day Low 0.1725
Address1 251 Consumers Road Shares Outstanding 19 M Compensation Risk 9
Price Hint 4 Target High Price 2.00 Website https://www.aptose.com
52 Week Change -0.9262 Average Volume 785157 Forward Eps -2.19
Recommendation Key buy Compensation As Of Epoch Date 1 B Last Split Factor 1:12
Regular Market Day High 0.1900 Is_sp_500 False Profit Margins 0.00 %
Fifty Two Week High 2.91 Day High 0.1900 Shares Short 120723
Regular Market Open 0.1893 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0062 Currency USD
Time Zone Full Name America/New_York Market Cap 10 M Is_nasdaq_100 False
Zip M2J 4R3 Quote Type EQUITY Industry Biotechnology
Long Name Aptose Biosciences Inc. Overall Risk 9 Regular Market Day Low 0.1725
Held Percent Institutions 0.1668 Current Price 0.1790 Address2 Suite 1105
Financial Currency USD Current Ratio 0.00 Industry Disp Biotechnology
Number Of Analyst Opinions 1 Country Canada Float Shares 11 M
Two Hundred Day Average 0.8562 Governance Epoch Date 1 B Forward PE -0.0817
Regular Market Volume 1 M Ebitda -36155000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States.

The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia.

It has license agreements with CrystalGenomics Invites Co.

Ltd.

to research, develop, and commercialize luxeptinib; and Hanmi Pharmaceutical Co Ltd.

to research, develop, and commercialize tuspetinib.

The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014.

Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.